Results 101 to 110 of about 17,558 (167)

GLP‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Type 1 Diabetes: A Propensity‐Matched Real‐World Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6347-6357, July 2026.
ABSTRACT Aims Evidence on cardiovascular/renal outcomes associated with GLP‐1‐based therapies in type 1 diabetes (T1D) is limited. We examined the effects of GLP‐1‐based therapy on major clinical outcomes and safety, including diabetic ketoacidosis (DKA) and hypoglycemia risk, in adults with T1D in a large real‐world cohort.
Anastasios Tentolouris, Charalampos Filippatos, Nikolaos‐Iason Tepetes, Maria Gavriatopoulou, Evangelos Terpos, Alexandros Briasoulis, Kimon Stamatelopoulos, Theodosios Filippatos   +7 more
wiley   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists in Cocaine Use Disorder: Clinical Observations and Underlying Mechanisms

Fundamental &Clinical Pharmacology, Volume 40, Issue 4, July 2026.
ABSTRACT Background Cocaine use disorder (CUD) remains a major public health concern, characterized by high relapse rates and the absence of approved pharmacological treatments. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA), widely prescribed for metabolic disorders, modulate mesolimbic reward pathways and have been proposed as potential ...
Céline Eiden, Ghjulia Chautard, Anne Batisse, Aurélie Aquizerate, Amandine Luquiens, Hélène Donnadieu, Jean‐Luc Faillie, Hélène Peyriere   +7 more
wiley   +1 more source

Methamphetamine-like discriminative-stimulus effects of nicotinic agonists. [PDF]

J Pharmacol Exp Ther, 2014
Desai RI, Bergman J.
europepmc   +1 more source

LRRK2 Mutation Alters Dopamine D2 Receptor Localization in Induced Pluripotent Stem Cells‐Derived Astrocytes From Parkinson's Disease Patients: Implications for Neuronal Damage

Journal of Neurochemistry, Volume 170, Issue 7, July 2026.
In this study, human astrocytes were obtained from induced pluripotent stem cells (iPSCs) of Parkinson's disease (PD) patients carrying the G2019S LRRK2 mutation, the most common genetic cause of PD. These astrocytes display a reactive and inflammatory profile, with increased GFAP levels, elevated cytokine release, and reduced support for dopaminergic ...
Veronica Mutti, Federica Bono, Zaira Tomasoni, Dounia Fadel, Chiara Gnutti, Giulia Sbrini, Carolina Gaudenzi, Valentina Salvi, Daniela Bosisio, Isabella Russo, Silvia Bolognin, Jens C. Schwamborn, Cristina Missale, Chiara Fiorentini   +13 more
wiley   +1 more source

Alpha-7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: A translational meta-analysis of rodent and human studies. [PDF]

Prog Neuropsychopharmacol Biol Psychiatry, 2017
Lewis AS, van Schalkwyk GI, Bloch MH.
europepmc   +1 more source

Targeted Mutations Activate Allosteric Modulation of α5-Containing Nicotinic Acetylcholine Receptors. [PDF]

ACS Chem Neurosci
Marotta CB, Lester HA, Dougherty DA.
europepmc   +1 more source

Drug Discovery Targeting Nicotinic Acetylcholine Receptors for Hearing Loss. [PDF]

Int J Mol Sci
Oman J, Sapkota P, Mateen S, Schulte M, Pashikanti S.   +4 more
europepmc   +1 more source

A new framework for nicotinic receptor-targeted therapeutic strategies in psychiatric and neurodegenerative disorders. [PDF]

Front Cell Neurosci
Oudaha K, Causeret F, Koukouli F.
europepmc   +1 more source

Nicotinic acetylcholine receptors in pain modulation. [PDF]

Front Pharmacol
Cheng J, Chang J, Li S.
europepmc   +1 more source

Putative α7-selective ligands interact with α9-containing nicotinic acetylcholine receptors and modulate immune functions of human mononuclear phagocytes. [PDF]

Front Immunol
Mobasher M, Hone AJ, Pilzecker M, Bozic D, Hecker A, McIntosh JM, Kirschner KN, Grau V, Papke RL, Andleeb H, Richter K.   +10 more
europepmc   +1 more source